Default company panoramic image

NeoForce Group, Inc.

NeoForce has created the worlds first combination Resuscitator/CPAP device and has revolutionized delivery of rescue breaths during CPR.

  • Stage $1M in TTM Revenue
  • Industry Medical Devices and Equipment
  • Location Ivyland, PA, USA
  • Currency USD
  • Founded June 2006
  • Employees 8
  • Website

Company Summary

NeoForce finds unmet needs in neonatal, pediatric and adult resuscitation and creates proprietary solutions for hospitals and first responders. Valued at $780M, the addressable market opportunity for our solutions is significant and sustainable. Baby-boomers are creating a rapidly growing aging population, resulting in increased demand for products addressing acute cardiopulmonary events with an expectation of better outcomes.


  • Default avatar
    Otho Boone
    President and CEO

    Otho Boone, founder and CEO, is a 27 year veteran in the global medical device market. He has run mid sized device companies for Hill-Rom (NYSE:HRC) and been part of smaller start-ups in the neonatal space. Otho is classically trained in mechanical engineering and holds multiple patents. He has hands on management experience in all aspects of medical device design, development, marketing, sales, operations and business development.

  • Default avatar
    Monica Ferrante
    Chief Regulatory Officer

    Monica Ferrante has 26 years of experience in medical device regulation and product design. She has spent time at HP and start-ups such as Animas. Monica holds a DPA from USC and has spent time at the FDA. This combination of technical and regulatory skills, allow us to efficiently move ideas into saleable product.

  • Default avatar
    Mark DeStefano
    Chief Technology Officer

    Mark DeStefano is a seasoned system engineer and has spent the past 27 years innovating products for Bell Labs, and J&J, as well as smaller start-ups such as Animas, Surgical Laser Technologies and NeoForce. He has patents in a variety of medical device development areas and has also consulted on several drug delivery devices.


  • Default avatar
    Blank Rome LLP
    Default avatar
    Jack Durkin Associates

Previous Investors

  • Default avatar
    Ben Franklin INvestment Partners